Tesamorelin Acetate


CAS No. : 901758-09-6

Tesamorelin Acetate,901758-09-6
Product Details
Cat No:P000411
Molecular Formula:C221H366N72O67S.(C2H4O2)x
Molecular Weight:5195.877
Price:Get quote
Inventory Status:In Stock
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh

Sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL

Purity: 98%

Cat No:P000411
Cas No:901758-09-6
Product-Name:Tesamorelin Acetate
InChIKey:LAJZPRPPHHRDIK-BCEXXFMNSA-N
1. Ann Pharmacother. 2012 Feb;46(2):240-7. doi: 10.1345/aph.1Q629. Epub 2012 Jan 31.

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

Spooner LM(1), Olin JL.
Author information:
(1)School of Pharmacy-Worcester/Manchester, Massachusetts College of Pharmacy and Health Sciences, USA. linda.spooner@mcphs.edu
OBJECTIVE: To evaluate the efficacy and safety of tesamorelin, a growth hormone releasing factor analogue approved by the Food and Drug Administration in November 2010 for the treatment of lipodystrophy associated with HIV infection. DATA SOURCES: Literature was obtained through MEDLINE (1948-November 2011) and International Pharmaceutical Abstracts (1970-October 2011) using the search terms tesamorelin, TH9507, growth hormone releasing factor, and HIV-associated lipodystrophy syndrome. Additional publications were obtained through review of references within primary literature publications as well as pertinent Web sites. STUDY SELECTION AND DATA EXTRACTION: All articles published in English identified from the data sources were evaluated and all pertinent information was included. All studies relevant to the evaluation of efficacy and safety of tesamorelin in the management of HIV-associated lipodystrophy were included, with a focus on trials completed in humans. DATA SYNTHESIS: In 2 Phase 3 clinical trials and their pooled analyses, tesamorelin was proven to significantly decrease waist circumference and visceral adipose tissue (VAT) following 26 weeks of treatment. Both trials also demonstrated significant improvements in some subjective body image parameters. Both studies had 26-week extension phases that confirmed maintenance of VAT improvements on treatment without adverse impact on blood glucose and lipid parameters. Limited data support off-label uses of tesamorelin at this time. CONCLUSIONS: Tesamorelin is effective in improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26-52 weeks of treatment. Potential limitations for its use include high cost and lack of long-term safety and adherence data. Tesamorelin provides a useful treatment option for management of patients with significant lipodystrophy related to HIV infection.

2. Curr Opin Investig Drugs. 2006 Oct;7(10):936-45.

Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.

Tomlinson B(1).
Author information:
(1)The Chinese University of Hong Kong, Division of Clinical Pharmacology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China. btomlinson@cuhk.edu.hk

Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin.
Recommended Products
  • CAS No. :150667-24-6
    Product Name:

    4-Acetamidoacetophenone

    Cat No: M098401 View details
  • CAS No. :158906-40-2
    Product Name:

    2,3-Dihydro-3-methyl-1,2,6,7-tetrahydroxy-1H-benzo(a)fluorene-4,11-dio ne

    Cat No: M098402 View details
  • CAS No. :156206-15-4
    Product Name:

    1,6,7,8-Indolizinetetrol, octahydro-, 6-methanesulfonate, 1S-(1.alpha.,6.beta.,7.alpha.,8.beta.,8a.b

    Cat No: M098403 View details
  • CAS No. :143328-91-0
    Product Name:

    4(1H)-Pyrimidinone, 2-ethyl-5-fluoro- (9CI)

    Cat No: M098404 View details